Targeting Pulmonary Artery Infusion of Nuclear-Targeted Plasmid-Based Short Hairpin RNA (ShRNA) to Hypoxia Inducible Factor-1α3 (pshHIF-1α3) Nano-Microspheres for Treatment of Implanted Lung Cancer in Rats

Abstract

The pshHIF-1α3 stealth nanospheres have been studied if they have the function of arterial targeted drug delivery to provide a new arterial targeted drug delivery method for interventional therapy of lung cancer. The study is also aimed at exploring therapeutic effect of the checked drug delivery on lung cancer. The tested groups were designed as follows: Group I: blank control group (pulmonary artery perfusion of 0.5 mL 0.9% saline); group II: tail vein injection of pshHIF-1α3 nano-microsphere; group III: pshHIF-1α3 nano-microsphere pulmonary artery perfusion group. In vitro experiment assessed the effects of pulmonary artery perfusion of pshHIF-1α3 nanospheres on proliferation, apoptosis and colony forming ability of lung cancer A549 cells, which were all evaluated by using MTT method, flow cytometry and colony formation experiments, respectively. In vivo experiment tumor xenotransplantation was used to observe the effect of pulmonary artery perfusion of pshHIF-1α3 nanospheres on treatment of lung cancer. Both the In vivo pulmonary artery perfusion experiment and In vitro experiments in A549 cells confirmed that the pulmonary artery perfusion of pshHIF-1α3 nano-microspheres can inhibit the proliferation of lung cancer tissues and cells, promoting apoptosis and inhibiting migration, leading to enhanced therapeutic effect of lung cancer. One of characteristics of nanomaterials is their large surface area, high dispersion, specific adhesion, tumor-specific affinity and adhesion, thereby prolonging their circulation time in the body. Through aggregation of nanodrug delivery system in tumor cells, the local concentration of the drug is increased, thereby improving selectivity of chemotherapeutic drugs. The results from this study therefore suggest that pulmonary artery perfusion of pshHIF-1α3 may be used in arterial targeted drug delivery for treatment of lung cancer, providing a new and efficient targeted drug delivery arterial route for interventional therapy of lung cancer.